HSK50042
/ Haisco
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 28, 2026
IPF: Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis
(clinicaltrials.gov)
- P2 | N=175 | Not yet recruiting | Sponsor: Haisco Pharmaceutical Group Co., Ltd.
New P2 trial • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
1 to 1
Of
1
Go to page
1